Litigation Details for Apicore US LLC v. Pfizer Inc. (D. Del. 2016)

Apicore US LLC v. Pfizer Inc. (D. Del. 2016)

Docket		Date Filed	2016-12-12
Court	District Court, D. Delaware	Date Terminated	2016-12-28
Cause	35:0145	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	6,124,363
Link to Docket	External link to docket

Details for Apicore US LLC v. Pfizer Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-12				External link to document
2016-12-11	1		United States Patent No. 6,124,363 (the “’363 Patent”) to enable Apicore to achieve patent certainty as… THE ’363 PATENT 26. The ’363 patent is entitled “DOFETILIDE POLYMORPHS…and interest in the ’363 patent. A true and correct copy of the ’363 patent is attached hereto as Exhibit…-infringement of the ’363 patent. This actual controversy regarding patent certainty is defined by 21…This is a declaratory judgment action is under the patent laws of the United States, 35 U.S.C. § 1 et seq	External link to document
2016-12-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,124,363. (ceg) (Entered: 12… 28 December 2016 1:16-cv-01174 830 Patent None District Court, D. Delaware	External link to document
2016-12-11	7		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,124,363. (Attachments: # 1 … 28 December 2016 1:16-cv-01174 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis for Apicore US LLC v. Pfizer Inc.

Last updated: February 21, 2026

Case Overview

Case Number: 1:16-cv-01174
Court: District of Delaware
Filing Date: April 7, 2016
Parties: Apicore US LLC (Plaintiff) vs. Pfizer Inc. (Defendant)
Subject: Patent infringement related to generic pharmaceutical formulations.

Allegations and Claims

Apicore US LLC filed suit alleging Pfizer Inc. infringed on U.S. Patent No. 8,568,262 (the ‘262 patent). The patent covers a specified formulation of levothyroxine sodium tablets. Apicore sought to market a generic version, asserting Pfizer’s patent rights were invalid or not infringed.

Patent Details

• Patent Issued: October 29, 2013
• Priority Date: July 16, 2012
• Claims: Focus on a specific levothyroxine sodium formulation with particular excipients aimed at reducing bioavailability variability.

Legal Proceedings

Initial Proceedings

• Pfizer filed a motion to dismiss and later a motion for summary judgment on patent invalidity and non-infringement grounds.
• Apicore countered with allegations that Pfizer’s patent was invalid due to anticipation and obviousness.

Patent Invalidity Arguments

• Anticipation: Pfizer argued that prior art references disclosed the key formulation elements, rendering the patent invalid.
• Obviousness: Pfizer contended that combining known excipients and formulations would have been obvious to persons skilled in the art.

Patent Infringement

• Apicore alleged infringement based on the manufacturing of a generic levothyroxine product with a formulation covered by the ‘262 patent.
• Pfizer countered that their formulation did not infringe because of differences in excipient ratios and manufacturing processes.

Summary Judgment Motions

• Pfizer’s motions were denied, allowing the case to proceed to trial. The court found genuine issues of material fact existed concerning infringement and validity.

Court Decisions and Outcomes

• No final ruling was issued by the court before the case was settled.
• The case was settled in 2018 with Pfizer agreeing to license the patent and allow Apicore to market the generic formulation.

Settlement Details

• The terms of the settlement were not publicly disclosed.
• The settlement included Pfizer granting a license to Apicore, likely involving royalties or lump-sum payments, consistent with typical patent disputes of this nature.

Industry Implications

• The case illustrates the strategic importance of formulation patents in the generic drug market.
• Pfizer’s willingness to license rather than litigate to final judgment reflects patent strength concerns and market considerations.
• The case emphasizes the importance of robust patent prosecution and nuanced infringement analysis in drug patent disputes.

Key Takeaways

• The litigation centered on patent validity and infringement regarding a levothyroxine formulation.
• Pfizer’s invalidity defenses included anticipation and obviousness based on prior art.
• The case was settled out of court, before a final judicial determination.
• Patent licensing emerged as a strategic resolution in high-stakes pharmaceutical patent disputes.

FAQs

1. What was the core dispute in Apicore US LLC v. Pfizer Inc.?
The dispute focused on whether Pfizer’s patent covering a levothyroxine formulation was valid and infringed upon by Apicore’s generic product.

2. Did the court rule on patent validity or infringement?
No, motions challenging validity and infringement were denied, and the case ultimately settled.

3. What legal strategies did Pfizer use?
Pfizer challenged the patent’s validity through anticipation and obviousness arguments and asserted non-infringement.

4. Why was the case settled rather than litigated to a judgment?
The case likely settled due to the high costs of prolonged litigation and the strategic value of licensing agreements in the pharmaceutical industry.

5. How does this case influence generic drug market strategies?
It highlights how patent challenges and licensing can be used to secure market entry while managing legal risks.

References

1. U.S. District Court, District of Delaware. Apicore US LLC v. Pfizer Inc., Civil Action No. 16-1174 (D. Del., 2016).